Nelida Noguera

Prof. Nelida Noguera

Tor Vergata University Rome Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Nelida NogueraNelida Noguera
Nelida Noguera
GCGianfranco Catalano
Gianfranco Catalano
CBC. Banella
C. Banella
MDM. Divona
M. Divona
Isabella FaraoniIsabella Faraoni
Isabella Faraoni
MVMaria Teresa Voso
Maria Teresa Voso
This review highlights new findings that have deepened our understanding of the mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia (APL). Promyelocytic leukemia-retinoic acid receptor α (PML-RARa) sets the cellular landscape of acute promyelocytic leukemia (APL) by repressing the transcription of RARa target genes and disrupting PML-NBs. The RAR receptors control the homeostasis of tissue growth, modeling and regeneration, and PML-NBs are involved in self-renewal of normal and cancer stem cells, DNA damage response, senescence and stress response. The additional somatic mutations in APL mainly involve FLT3, WT1, NRAS, KRAS, ARID1B and ARID1A genes. The treatment outcomes in patients with newly diagnosed APL improved dramatically since the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). ATRA activates the transcription of blocked genes and degrades PML-RARα, while ATO degrades PML-RARa by promoting apoptosis and has a pro-oxidant effect. The resistance to ATRA and ATO may derive from the mutations in the RARa ligand binding domain (LBD) and in the PML-B2 domain of PML-RARa, but such mutations cannot explain the majority of resistances experienced in the clinic, globally accounting for 5–10% of cases. Several studies are ongoing to unravel clonal evolution and resistance, suggesting the therapeutic potential of new retinoid molecules and combinatorial treatments of ATRA or ATO with different drugs acting through alternative mechanisms of action, which may lead to synergistic effects on growth control or the induction of apoptosis in APL cells.

7 November 2012 in Leukemia
Verified
Journal Article
Closed access
Nelida NogueraNelida Noguera
Nelida Noguera
MSM S Song
M S Song
MDM Divona
M Divona
GCG Catalano
G Catalano
KCK L Calvo
K L Calvo
FLF Lo-Coco
F Lo-Coco

22 June 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
GCGianfranco Catalano
Gianfranco Catalano
AZAlessandra Zaza
Alessandra Zaza
CBCristina Banella
Cristina Banella
EPElvira Pelosi
Elvira Pelosi
GCGermana Castelli
Germana Castelli
Nelida NogueraNelida Noguera
Nelida Noguera

14 May 2025 in Cells
Verified
Journal Article
Open access
PDF file
SHSyed Hasan
Syed Hasan
SJSundarraj Jayakumar
Sundarraj Jayakumar
EBEliezer Espina Barroso
Eliezer Espina Barroso
AJAnup Jha
Anup Jha
GCGianfranco Catalano
Gianfranco Catalano
Nelida NogueraNelida Noguera
Nelida Noguera
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor that plays a central role in regulating cellular responses to oxidative stress. It governs the expression of a broad range of genes involved in antioxidant defense, detoxification, metabolism, and other cytoprotective pathways. In normal cells, the transient activation of Nrf2 serves as a protective mechanism to maintain redox homeostasis. However, the persistent or aberrant activation of Nrf2 in cancer cells has been implicated in tumor progression, metabolic reprogramming, and resistance to chemotherapy and radiotherapy. These dual roles underscore the complexity of Nrf2 signaling and its potential as a therapeutic target. A deeper understanding of Nrf2 regulation in both normal and malignant contexts is essential for the development of effective Nrf2-targeted therapies. This review provides a comprehensive overview of Nrf2 regulation and function, highlighting its unique features in cancer biology, particularly its role in metabolic adaptation and drug resistance. Special attention is given to the current knowledge of Nrf2′s involvement in leukemia and emerging strategies for its therapeutic modulation.

5 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
JAJacopo Albanesi
Jacopo Albanesi
Nelida NogueraNelida Noguera
Nelida Noguera
CBCristina Banella
Cristina Banella
TCTommaso Colangelo
Tommaso Colangelo
EMElisabetta De Marinis
Elisabetta De Marinis
Alessandra Di MasiAlessandra Di Masi
Alessandra Di Masi
Acute promyelocytic leukemia (APL) is a hematological disease characterized by a balanced reciprocal translocation that leads to the synthesis of the oncogenic fusion protein PML-RARα. APL is mainly managed by a differentiation therapy based on the administration of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, therapy resistance, differentiation syndrome, and relapses require the development of new low-toxicity therapies based on the induction of blasts differentiation. In keeping with this, we reasoned that a better understanding of the molecular mechanisms pivotal for ATRA-driven differentiation could definitely bolster the identification of new therapeutic strategies in APL patients. We thus performed an in-depth high-throughput transcriptional profile analysis and metabolic characterization of a well-established APL experimental model based on NB4 cells that represent an unevaluable tool to dissect the complex mechanism associated with ATRA-induced granulocytic differentiation. Pathway-reconstruction analysis using genome-wide transcriptional data has allowed us to identify the activation/inhibition of several cancer signaling pathways (e.g., inflammation, immune cell response, DNA repair, and cell proliferation) and master regulators (e.g., transcription factors, epigenetic regulators, and ligand-dependent nuclear receptors). Furthermore, we provide evidence of the regulation of a considerable set of metabolic genes involved in cancer metabolic reprogramming. Consistently, we found that ATRA treatment of NB4 cells drives the activation of aerobic glycolysis pathway and the reduction of OXPHOS-dependent ATP production. Overall, this study represents an important resource in understanding the molecular “portfolio” pivotal for APL differentiation, which can be explored for developing new therapeutic strategies.

9 December 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MPMaria Liliana Piredda
Maria Liliana Piredda
GGGirish Gaur
Girish Gaur
GCGianfranco Catalano
Gianfranco Catalano
MDMariadomenica Divona
Mariadomenica Divona
CBCristina Banella
Cristina Banella
Nelida NogueraNelida Noguera
Nelida Noguera